|View printer-friendly version|
|February 02, 2017 8:00 a.m.|
|Teva Confirms Generic Victoza® Patent Challenge in the United States|
Based on available information, Teva believes it is a "first applicant" to file an ANDA for the generic version of Victoza®; should its ANDA be approved, Teva may be entitled to 180 days of generic market exclusivity.
For the 12 months ending
With nearly 600 generic medicines available, Teva has the largest
Teva's Safe Harbor Statement under the
Teva Pharmaceuticals Industries Ltd.